Laboratory LESCUYER® Receives EFSA Approval

LA ROCHELLE, FranceLaboratory LESCUYER® received a positive opinion from European Food and Safety Authority (EFSA) for a health claim under Article 14 for its product LIMICOL®.

According to Laboratory LESCUYER®, this is the first time a patented dietary supplement has ever received a favorable opinion for a health claim in Europe. LIMICOL® is also the first dietary supplement to benefit from the protection of proprietary data relating to a disease risk claim.

Laboratory LESCUYER® is waiting on final approval from the European Commission to state this recognition on its patented formula.

EFSA represents the highest European authority for food safety and consists of a panel of experts in nutrition. EFSA scientifically recognized the health benefits of LIMICOL® and its claims to reduce blood LDL-cholesterol concentrations.

LIMICOL® contains artichoke extract, red yeast rice, garlic extract, vitamins B2, B3 and E. LIMICOL's effectiveness is based on the synergistic action of eight selected assets along with a well balanced diet and healthy lifestyle.

According to Laboratory LESCUYER®, the company conducted five years of research to submit a complete scientific document that included the results of three proprietary clinical studies to the EFSA.

The company developed a team of medical scientists that worked closely with external contributors to produce the elements for the health claim application. Independent research groups conducted three clinical trials that included a double-blind and placebo-controlled randomized studies on 184 volunteers.